Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

[11] Cloutier M(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-44

[12] Velligan DI(2007)Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States Curr Med Res Opin 23 2305-226

[13] Weiden PJ(2017)Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness Patient Prefer Adherence 11 449-1048

[14] Sajatovic M(2013)World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 14 2-331

[15] Bright CE(2013)Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies World Psychiatry 12 216-624

[16] Yang J(2017)Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly Adv Ther 34 1036-24

[17] Ko Y-H(2017)Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study J Clin Psychiatry 78 324-241

[18] Paik J-W(2012)Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study J Clin Psychiatry 73 617-35S

[19] García S(2016)The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence J Clin Psychiatry 77 1-219

[20] Martínez-Cengotitabengoa M(2015)Guidelines for the use of second-generation long-acting antipsychotics Psychiatr Pol 49 225-134

[11] Cloutier M(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-44

[12] Velligan DI(2007)Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States Curr Med Res Opin 23 2305-226

[13] Weiden PJ(2017)Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness Patient Prefer Adherence 11 449-1048

[14] Sajatovic M(2013)World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 14 2-331

[15] Bright CE(2013)Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies World Psychiatry 12 216-624

[16] Yang J(2017)Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly Adv Ther 34 1036-24

[17] Ko Y-H(2017)Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study J Clin Psychiatry 78 324-241

[18] Paik J-W(2012)Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study J Clin Psychiatry 73 617-35S

[19] García S(2016)The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence J Clin Psychiatry 77 1-219

[20] Martínez-Cengotitabengoa M(2015)Guidelines for the use of second-generation long-acting antipsychotics Psychiatr Pol 49 225-134